Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY17550 Internet Delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS) To determine whether an Internet-based pain coping skills program plus enhanced usual care, compared to enhanced usual care alone, yields significant improvements in the co-primary outcomes of pain severity (as measured by the Brief Pain Inventory (BPI)) and pain interference (also measured by the BPI) from baseline to the post-intervention assessment for cancer survivors with persistent pain. Study Information
STUDY12888 The Impact of a Gravity versus Vacuum Based Indwelling Tunneled Pleural Drainage System on Pain: A Multicenter, Randomized Trial The objective of this investigation is to compare different drainage strategies of Indwelling Pleural Catheters (IPC) regarding patient quality of life and outcomes Study Information
STUDY19497 A Randomized Controlled Trial to Evaluate the Survivorship Needs Assessment Planning Tool for Head and Neck Cancer Survivor Caregiver Dyads To evaluate the effects of SNAP on: a) caregiver burden in caregivers, b) symptom severity in survivors and c) psychological well-being in head and neck cancer survivors and caregivers 6 months after completing SNAP Study Information
STUDY18274 A Multi Site Randomized Clinical Trial Comparing a Brief Tele Cognitive Behavioral Therapy Intervention (BRIGHT) with Attention Control for the Management of Body Image Related Distress Among Head and Neck Cancer Survivors To evaluate the efficacy of BRIGHT compared with attention control (AC) on HNC-related BID as measured by change from baseline in the IMAGEHN score. Study Information
STUDY21729 Double Blind Randomized Controlled Trial Comparing Suvorexant 20 Mg to Placebo for Treatment of Insomnia in Cancer Survivors 1. To evaluate the self-reported efficacy of suvorexant for the treatment of insomnia in breast cancer survivors at least 6 weeks beyond completion of definitive treatment and less than 5 years from time of initial diagnosis. 2. To assess the impact of suvorexant on quality of life in breast cancer survivors. Study Information